Pfenex hires new chief financial officer

Pfenex, Inc., a clinical-stage biotechnology company, announced on Wednesday that it named Paul Wagner as its new chief financial officer.

Wagner has more than 15 years of experience in biotechnology and finance. He most recently served as the director, portfolio manager and senior equity analyst at Allianz Global Investors.

"Paul's impressive healthcare industry experience and demonstrated track record as a successful biotechnology and pharmaceutical executive makes him well suited to step into this important role on our management team," Bertrand Liang, the CEO of Pfenex, said. "We are excited to have Paul on board and look forward to his finance, strategic, and operating contributions at Pfenex."

Prior to working at Allianz, Wagner served as the head of development licensing, corporate and business development at PDL Biopharma, a company engaging in the humanization of monoclonal antibodies.

"I am honored to be joining the dedicated and talented team at Pfenex," Wagner said. "In addition to overseeing the financial functions of the company, I look forward to contributing to the transition of Pfenex to a late-stage clinical development and commercial organization, as it continues to advance its portfolio of biosimilar product candidates and innovative vaccines."

In April, Pfenex and Immunovaccine, Inc., announced positive results from anthrax challenge studies in rabbits involving Pfenex's mutant recombinant protective antigen (mrPA) . All rabbits protected with at least a third of a microgram of mrPA combined with Immunovaccine's DepoVax delivery system survived a lethal anthrax challenge.